Whitepaper: Tumor Mutational Burden
The Tumor Mutational Burden (TMB) is a genomic biomarker. Recent studies indicate that TMB
predicts clinical response to Immune Checkpoint Inhibitors (ICI) such as Keytruda (pembrolizumab)
even across all solid cancer types (5). However, other recent studies could not show a significant
association with efficacy of pembrolizumab plus carboplatin and pemetrexed or carboplatin and
pemetrexed alone as first-line therapy for metastatic nonsquamous NSCLC.
To download this whitepaper please submit the form below: